RxDoctor Payments Data

Benjamin Levin, MD

Internal Medicine · Hyannis, MANPI 1356631436

Payments from drug & device makers

$512in general payments, 2019–2025

Across 19 payments — averaging $26.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$243
  • Medtronic$105
  • E.r. Squibb & Sons, L.L.C.$101
  • Johnson & Johnson$47
  • AstraZeneca$15

What the payments were for

  • Food & beverage$512100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$512 in reported general payments places this provider in the 75th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$1,782,556
Medicare patients
1,300
Services billed
104,868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban123$117,947
XareltoRivaroxaban25$36,868
JardianceEmpagliflozin11$17,627
OzempicSemaglutide15$17,314
MounjaroTirzepatide13$13,299
Breo ElliptaFluticasone/Vilanterol12$6,917
Atorvastatin Calcium538$6,421
Metoprolol Succinate209$4,086
Losartan Potassium321$3,928
Rosuvastatin Calcium122$3,797
Omeprazole286$3,356
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$3,252
SynthroidLevothyroxine Sodium64$3,217
Albuterol Sulfate HfaAlbuterol Sulfate79$2,995
Valsartan91$2,859

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$243$117,947123 claims
Johnson & JohnsonXarelto$47$36,86825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Hyannis

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →